复合结局指标在银屑病关节炎试验中区分活性治疗与安慰剂的能力:GRAPPA-OMERACT系统评价与网络Meta分析
该研究系统检索了比较b-或tsDMARD与安慰剂的银屑病关节炎RCT,纳入24项试验43个随机比较,采用网络Meta分析和多变量Meta分析评估7种复合结局指标的区分能力。结果显示MDA、ACR20和PASDAS的区分能力优于DAPSA,ACR70在探索性分析中优于ACR20和DAPSA但不优于ACR50、MDA和PASDAS。
要点
- MDA、ACR20和PASDAS区分活性治疗与安慰剂的能力优于DAPSA。
- 多变量Meta分析中MDA的OR为5.06,高于ACR20的4.01和PASDAS的3.70。
- 探索性分析提示ACR70区分能力优于ACR20和DAPSA,但不优于ACR50、MDA和PASDAS。
核心结论
- ACR20、MDA和PASDAS在银屑病关节炎RCT中区分活性治疗与安慰剂的能力优于DAPSA。
- 探索性分析提示ACR70区分能力优于ACR20和DAPSA,但不优于ACR50、MDA和PASDAS。
研究设计与样本
- 系统文献综述(PROSPERO ID: CRD42024578203)检索Cochrane Central Register of Controlled Trials和PubMed,纳入比较b-或tsDMARD与安慰剂的RCT。
- 纳入标准为报告GRAPPA-OMERACT工作组短名单中7种复合结局指标中至少2种的RCT。
- 共纳入24项试验(43个随机比较),采用网络Meta分析和多变量Meta分析评估区分能力。
主要发现
- CPDAI很少被报告,无RCT报告3-VAS和4-VAS。
- 主网络Meta分析显示DAPSA vs ACR20的OR为0.80(95%CI: 0.66-0.97), favouring ACR20。
- 主网络Meta分析显示DAPSA vs MDA的OR为0.71(95%CI: 0.57-0.87), favouring MDA。
- 主网络Meta分析显示PASDAS vs DAPSA的OR为1.35(95%CI: 1.10-1.66), favouring PASDAS。
- 多变量Meta分析显示MDA的OR为5.06(95%CI: 4.20-6.09),ACR20为4.01(95%CI: 3.41-4.73),PASDAS为3.70(95%CI: 3.00-4.56),DAPSA为3.02(95%CI: 2.44-3.75),CPDAI为1.86(95%CI: 0.95-3.64)。
关键数值与推荐
- MDA多变量Meta分析OR为5.06(95%CI: 4.20-6.09)。
- ACR20多变量Meta分析OR为4.01(95%CI: 3.41-4.73)。
- PASDAS多变量Meta分析OR为3.70(95%CI: 3.00-4.56)。
- DAPSA多变量Meta分析OR为3.02(95%CI: 2.44-3.75)。
- CPDAI多变量Meta分析OR为1.86(95%CI: 0.95-3.64)。
临床怎么用
- 在银屑病关节炎RCT中,MDA、ACR20和PASDAS可能比DAPSA更能区分活性治疗与安慰剂。
- ACR70在探索性分析中显示较高区分能力,但需进一步验证。
局限性
- CPDAI很少被报告,无RCT报告3-VAS和4-VAS,可能限制这些指标的评价。
- ACR70的区分能力优势来自探索性分析,需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To identify which composite outcome measure most effectively distinguishes active treatments from placebo in randomised controlled trials (RCTs) of biologic or targeted synthetic disease-modifying antirheumatic drugs (b- or tsDMARDs) for psoriatic arthritis (PsA). METHODS: A systematic literature review (PROSPERO ID: CRD42024578203) of Cochrane Central Register of Controlled Trials and PubMed identified RCTs comparing b- or tsDMARDs with placebo reporting ≥2 of 7 composite outcome measures shortlisted for evaluation by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis-Outcome Measures in Rheumatology (GRAPPA-OMERACT) working group (American College of Rheumatology Response Criteria [ACR], Composite Psoriatic Disease Activity Index [CPDAI], Disease Activity index for PSoriatic Arthritis [DAPSA], Minimal Disease Activity [MDA], Psoriatic Arthritis Disease Activity Score [PASDAS], and 3- and 4-Visual Analogue Scale [VAS]). Discriminant capacities were assessed using odds ratio (OR) for binary outcomes, with continuous outcomes converted from standardised mean differences and analysed through network and multivariate meta-analysis techniques. RESULTS: Of 2483 references, 24 trials were included (43 randomised comparisons). CPDAI was rarely reported, and no RCTs reported 3-VAS and 4-VAS. The main network meta-analysis showed differences in discriminant properties for DAPSA vs ACR20 (OR: 0.80; 95% CI: 0.66-0.97; favouring ACR20), DAPSA vs MDA (OR: 0.71; 0.57-0.87; favouring MDA), and PASDAS vs DAPSA (OR: 1.35; 1.10-1.66; favouring PASDAS). Supported by multivariate meta-analysis: MDA (OR: 5.06; 4.20-6.09), ACR20 (OR: 4.01; 3.41-4.73), PASDAS (OR:3.70; 3.00-4.56), DAPSA (OR: 3.02; 2.44-3.75), and CPDAI (OR: 1.86; 0.95-3.64). Sensitivity analyses confirmed a pattern of consistent numerical advantages for MDA and PASDAS. Exploratory analyses showed ACR70 had more discriminant capacity than ACR20 and DAPSA but not ACR50, MDA, and PASDAS. CONCLUSIONS: ACR20, MDA, and PASDAS demonstrated greater discriminant capacity than DAPSA. Exploratory analyses suggested greater discriminant capacity for ACR70 compared with ACR20 and DAPSA but not with ACR50, MDA or PASDAS.
引用
- Annfeldt TK, Händel MN, Haugegaard T, et al. Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials: a GRAPPA-OMERACT systematic review and network meta-analysis. Ann Rheum Dis. 2026. PMID: 42248769. doi:10.1016/j.ard.2026.05.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。